Search Results - Tahami Monfared, AA

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

    Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes by Gibson, E J, Begum, N, Koblbauer, I, Dranitsaris, G, Liew, D, McEwan, P, Tahami Monfared, A A, Yuan, Y, Juarez-Garcia, A, Tyas, D, Lees, M

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

    Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada by Quon, P, Xiao, Y, Sorensen, S, Schultz, M, Tahami Monfared, AA

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    EE141 Impact of Mode of Drug Delivery Administration on Healthcare Costs in a Medicare Fee for Service Population

    EE141 Impact of Mode of Drug Delivery Administration on Healthcare Costs in a Medicare Fee for Service Population by Zhang, H, Zhang, Q, Nair, K, Gao, R, Haji, B, Tahami Monfared, AA

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    EPH45 Increased Access to Subcutaneous Relative to Intravenous Drug Regimens by Women and Minority Racial/Ethnic Patients Using Belimumab or Tocilizumab Among US Medicare Beneficiaries

    EPH45 Increased Access to Subcutaneous Relative to Intravenous Drug Regimens by Women and Minority Racial/Ethnic Patients Using Belimumab or Tocilizumab Among US Medicare Beneficia... by Gao, R, Nair, K, Zhang, R, Haji, B, Zhang, Q, Tahami Monfared, AA

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    PCN165 - Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

    PCN165 - Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada by Quon, P, Xiao, Y, Sorensen, S, Schultz, M, Tahami Monfared, AA

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    PIN10 COMPARATIVE (POSACONAZOLE VS. OTHER SYSTEMIC ANTIFUNGALS) ALL-CAUSE MORTALITY AND COST ANALYSIS IN PATIENTS WITH REFRACTORY INVASIVE ASPERGILLOSIS

    PIN10 COMPARATIVE (POSACONAZOLE VS. OTHER SYSTEMIC ANTIFUNGALS) ALL-CAUSE MORTALITY AND COST ANALYSIS IN PATIENTS WITH REFRACTORY INVASIVE ASPERGILLOSIS by Tahami Monfared, AA, Rajagopalan, S, Danna, R, Papadopoulos, G

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    PIN16 COST-EFFECTIVENESS OF POSACONAZOLE VS. FLUCONAZOLE IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE IN CANADA

    PIN16 COST-EFFECTIVENESS OF POSACONAZOLE VS. FLUCONAZOLE IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE IN CANADA by Tahami Monfared, AA, O'Sullivan, AK, Papadopoulos, G

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    PIN13 ECONOMIC EVALUATION OF POSACONAZOLE VS. STANDARD AZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH PROLONGED NEUTROPENIA IN CANADA

    PIN13 ECONOMIC EVALUATION OF POSACONAZOLE VS. STANDARD AZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH PROLONGED NEUTROPENIA IN CANADA by Tahami Monfared, AA, O'Sullivan, AK, Papadopoulos, G

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    PMD21: A RELIABLE AND ROBUST ALGORITHM TO DETERMINE IN-HOSPITAL LENGTH OF STAY AND READMISSIONS USING RAMQ

    PMD21: A RELIABLE AND ROBUST ALGORITHM TO DETERMINE IN-HOSPITAL LENGTH OF STAY AND READMISSIONS USING RAMQ by Tahami Monfared, AA, LeLorier, J

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    PMH7: A MARKOV COHORT SIMULATION ESTIMATING THE RISK OF DEVELOPING CORONARY HEART DISEASE IN PATIENTS USING ANTIPSYCHOTIC DRUGS

    PMH7: A MARKOV COHORT SIMULATION ESTIMATING THE RISK OF DEVELOPING CORONARY HEART DISEASE IN PATIENTS USING ANTIPSYCHOTIC DRUGS by Tahami Monfared, AA, Gueylard Chenevier, D, Lescrauwaet, B, LeLorier, J

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: